HUE033256T2 - Kétfázisú lipidvezikulum készítmény és eljárás cervikális diszplázia kezelésére intravaginális adagolással - Google Patents
Kétfázisú lipidvezikulum készítmény és eljárás cervikális diszplázia kezelésére intravaginális adagolással Download PDFInfo
- Publication number
- HUE033256T2 HUE033256T2 HUE08733666A HUE08733666A HUE033256T2 HU E033256 T2 HUE033256 T2 HU E033256T2 HU E08733666 A HUE08733666 A HU E08733666A HU E08733666 A HUE08733666 A HU E08733666A HU E033256 T2 HUE033256 T2 HU E033256T2
- Authority
- HU
- Hungary
- Prior art keywords
- composition
- alpha
- interferon alpha
- lipid
- human
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 87
- 206010008263 Cervical dysplasia Diseases 0.000 title claims description 33
- 238000000034 method Methods 0.000 title claims description 32
- 230000002051 biphasic effect Effects 0.000 title claims description 9
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 44
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 44
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 28
- 239000000839 emulsion Substances 0.000 claims description 26
- 239000012071 phase Substances 0.000 claims description 24
- 229930195722 L-methionine Natural products 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229960004452 methionine Drugs 0.000 claims description 18
- 239000006071 cream Substances 0.000 claims description 17
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 239000003623 enhancer Substances 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 6
- 239000007764 o/w emulsion Substances 0.000 claims description 6
- 206010058314 Dysplasia Diseases 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 4
- 229940124272 protein stabilizer Drugs 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 28
- 150000002632 lipids Chemical class 0.000 description 27
- 239000000232 Lipid Bilayer Substances 0.000 description 21
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 15
- 239000002502 liposome Substances 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000000306 component Substances 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000004033 plastic Substances 0.000 description 9
- 229920003023 plastic Polymers 0.000 description 9
- 108010050904 Interferons Proteins 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 108010047761 Interferon-alpha Proteins 0.000 description 7
- 102000006992 Interferon-alpha Human genes 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 6
- -1 e.g. Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229930186217 Glycolipid Natural products 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000009608 Papillomavirus Infections Diseases 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000003679 cervix uteri Anatomy 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000002573 colposcopy Methods 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 3
- 208000000260 Warts Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- 150000001783 ceramides Chemical class 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000009595 pap smear Methods 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 231100000057 systemic toxicity Toxicity 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 244000044822 Simmondsia californica Species 0.000 description 2
- 235000004433 Simmondsia californica Nutrition 0.000 description 2
- 206010070835 Skin sensitisation Diseases 0.000 description 2
- 208000032124 Squamous Intraepithelial Lesions Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 2
- 239000008163 avocado oil Substances 0.000 description 2
- 235000021302 avocado oil Nutrition 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000002640 perineum Anatomy 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 231100000370 skin sensitisation Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- BILPUZXRUDPOOF-UHFFFAOYSA-N stearyl palmitate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC BILPUZXRUDPOOF-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- VKCGSTZAZMNTRV-DHUJRADRSA-N (2s)-2,6-bis(hexadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)CCCCCCCCCCCCCCC VKCGSTZAZMNTRV-DHUJRADRSA-N 0.000 description 1
- TUBPSFQENHCYBW-HVDRVSQOSA-N (2s)-2-aminopentanedioic acid;2-[bis(2-hydroxyethyl)amino]ethanol Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OCCN(CCO)CCO TUBPSFQENHCYBW-HVDRVSQOSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- XIIAYQZJNBULGD-UHFFFAOYSA-N (5alpha)-cholestane Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XIIAYQZJNBULGD-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- VOFRZBBLONRUHY-KVVVOXFISA-N 2-(2-hydroxyethylamino)ethanol;2-[2-[2-[(z)-octadec-9-enoxy]ethoxy]ethoxy]ethyl dihydrogen phosphate Chemical compound OCCNCCO.CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOP(O)(O)=O VOFRZBBLONRUHY-KVVVOXFISA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- 244000068687 Amelanchier alnifolia Species 0.000 description 1
- 235000009027 Amelanchier alnifolia Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 235000014150 Myroxylon pereirae Nutrition 0.000 description 1
- 244000302151 Myroxylon pereirae Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- XMEKHKCRNHDFOW-UHFFFAOYSA-N O.O.[Na].[Na] Chemical compound O.O.[Na].[Na] XMEKHKCRNHDFOW-UHFFFAOYSA-N 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 102220606961 Ras-related protein Rap-1b_Q25A_mutation Human genes 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
- CFRNDJFRRKMHTL-UHFFFAOYSA-N [3-octanoyloxy-2,2-bis(octanoyloxymethyl)propyl] octanoate Chemical compound CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)(COC(=O)CCCCCCC)COC(=O)CCCCCCC CFRNDJFRRKMHTL-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 201000003565 cervix uteri carcinoma in situ Diseases 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- XIIAYQZJNBULGD-LDHZKLTISA-N cholestane Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XIIAYQZJNBULGD-LDHZKLTISA-N 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MQSDOCWFPKXZGN-ZZEZOPTASA-N docosyl (z)-docos-13-enoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCC\C=C/CCCCCCCC MQSDOCWFPKXZGN-ZZEZOPTASA-N 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108091005632 fatty acylated proteins Proteins 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 208000021145 human papilloma virus infection Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 229940028862 interferon gamma-1b Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- 239000001157 myroxylon pereirae klotzsch resin Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940079781 sodium cocoyl glutamate Drugs 0.000 description 1
- 229940045944 sodium lauroyl glutamate Drugs 0.000 description 1
- IWIUXJGIDSGWDN-UQKRIMTDSA-M sodium;(2s)-2-(dodecanoylamino)pentanedioate;hydron Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC(O)=O IWIUXJGIDSGWDN-UQKRIMTDSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000022159 squamous carcinoma in situ Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- ABTZKZVAJTXGNN-UHFFFAOYSA-N stearyl heptanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCC ABTZKZVAJTXGNN-UHFFFAOYSA-N 0.000 description 1
- 229940098758 stearyl heptanoate Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 229940100617 topical lotion Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940048912 triethanolamine cocoyl glutamate Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 208000022625 uterine cervix carcinoma in situ Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Description
(12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 38121 <20060i> A61K 31I198<200601> 16.11.2016 Bulletin 2016/46 A61K 9I06<2006 01> A61K 91107<2006 01> A61K 9H27<2006 01> A61K 9100 <2006 01> (21) Application number: 08733666.5 A61K 9110^1, A61K 47I18<2™”> (22) Date of filing: 27.03.2008 (86) International application number: PCT/CA2008/000563 (87) International publication number: WO 2008/119160 (09.10.2008 Gazette 2008/41)
(54) BIPHASIC LIPID-VESICLE COMPOSITION AND METHOD FOR TREATING CERVICAL DYSPLASIA BY INTRAVAGINAL DELIVERY
ZWEIPHASIGE LIPIDVESIKELZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON ZERVIXDYSPLASIE MITTELS INTRAVAGINALER VERABREICHUNG
COMPOSITION DE VESICULES LIPIDIQUES BIPHASIQUES ET PROCEDE DE TRAITEMENT D UNE DYSPLASIE DU COL DE L’UTERUS PAR ADMINISTRATION INTRAVAGINALE (84) Designated Contracting States: (74) Representative: Gibson, Mark
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Sagittarius IP HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT Three Globeside RO SE SI SK TR Fieldhouse Lane
Designated Extension States: Marlow, Buckinghamshire SL7 1HZ (GB)
AL BAMKRS (56) References cited: (30) Priority: 30.03.2007 US 909324 P WO-A1-95/03787 WO-A1-99/11247 US-B1- 6 656 499 (43) Date of publication of application: 23.12.2009 Bulletin 2009/52 · STELLATO G.:’Intralesional recombinant alpha 2b interferon in the treatment of human (73) Proprietor: Helix Biopharma Corp. papillomavirus-associated cervical
Toronto, ON M4T 1L9 (CA) intraepithelial neoplasia’ SEXUALLY: TRANSMITTED DISEASES vol. 19, no. 3, May 1992 (72) Inventors: - June 1992, pages 124 -126, XP008117821 • FOLDVARI, Marianna · YLISKOSKI Μ. ET AL.: ’Topical treatment with
Kitchener, Ontario N2C 2R2 (CA) human leukocyte interferon of HPV16 infections • KUMAR, Praveen associated with cervical and vaginal
Saskatoon, Saskatchewan S7J 4N3 (CA) intraepithelial neoplasias’ GYNECOLOGIC • DOCHERTY, John, M. ONCOLOGY vol. 36, no. 3, March 1990, pages 353
Richmond Hill, Ontario L4E 4S4 (CA) - 357, XP022986846
Description
Field of the Invention [0001] The present invention relates a biphasic lipid-vesicle composition and method for treating cervical displasia by intravaginal delivery.
Background of the Invention [0002] Of the estimated 55 million Pap smears performed each year in the United States, more than 5% are reported as abnormal (ALTS study 2003). An estimated 800,000 women each year present with low-grade squamous intraepithelial lesions (LSIL) (Jones, BA, Davey DD. Quality management in gynaecologic cytology using interlaboratory comparison. Arch Pathol Lab Med 2000;124(5):672-81).
[0003] These lesions will either progress with time to CIN 2-3 or invasive cancer, especially in women that present with the high-risk HPV-subtype, or regress with time in the absence of treatment. Of women diagnosed with LSIL, 25% will progress to cervical intraepithelial neoplasia (CIN) grade 2 or 3, 22-32% will have persistent CIN 1 and approximately 50%-70% will experience spontaneous regression of LSIL within 2 years (ALTS group 2003, Ostor AG Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol Pathol 1993;12:186-92). Approximately 75% will experience spontaneous regression within 5 years.
[0004] The cytologic LSIL definition of the Bethesda System is different from the Munich classification system used in Germany and throughout the EU. LSIL corresponds to condyloma or CIN 1 in the Bethesda System. In the Munich classification these findings are represented in the Pap groups II W-lll D. However, it should be noted that in group III D also patients with colposcopic diagnosis of CIN 2 (moderate dysplasia) are included.
[0005] At present, there is no immediate therapy available for women with HPV presenting with LSIL. Once a low-grade abnormal Pap smear has been detected, the patient and the clinician are left with the choice of either repeating it one or more times, or proceeding to colposcopy. Colposcopy is often accompanied by biopsy. Based on the findings of the colposcopy and biopsy, treatment options include conization, cryotherapy or laser treatment. Women who have undergone such treatment options may carry an increased risk of abortion and premature labor.
[0006] There are a number of clinical trials that have been published that describe interferons to be effective against a variety of HPV cervical infections. Studies on the use of interferons for the treatment of cervical intraepitehial neoplasia report cure rates between 0 - 100%. These variations most likely reflect differences in dosage, duration of treatment, mode of application, study design, severity of disease, and measures of efficacy.
[0007] In an open study, Penna et al. (1994) (Penna C, Fallan MG, Gordigiani R et al., Intralesional beta-interferon treatment of cervical intraepithelial neoplasia associated with human papillomavirus infection, Tumori 1994; 80:146-150) reported 80% lesion regression and 51% reversion of HPV type 16/18 to normal following daily intra-perilesionally application into the cervix in women with CIN associated with HPV infection of 3 MIU of IFN beta for 3 weeks. Similarly, in an open pilot study, Katesmark et al. (1999) (Katesmark M., Coulter Smith S., Reynolds K., Lawton F. A pilot study of the efficacy and tolderability of intralesional recombinant human beta interferons in cervical intraepithelial neoplasia. Ann Acad Singapore 1999; 28(6)775-7) showed a 73% histology complete response rate of CIN when IFN was injected into the transformation zone.
[0008] Schneider et al. (1995) (Schneider A, Grubert T, Kirchmayr R, Wagner D, Papendick U, Schlunck G. Efficacy trial of topically administered Interferon gamma-1 b gel in comparison to laser treatment in cervical intraepithelial neoplasia. Arch Gynecol Obstet 1995; 256:75-83) reported a 42% complete response, 42% partial response following IFN-gamma 1 b gel therapy in women with CIN. In this study, patients with CIN II responded better compared with CIN III. It is also of interest to note that smokers showed a significantly lower cure rate when compared to non-smokers.
[0009] Zarcone et al. (1995) (Zarcone R., Bellini P., Cardone G., Cardone A. Treatment of cervix condylomata with alpha-IFN leucocytar. Clin Exp Obst Gyn 1995;22(4):326-9) have reported success in a small, 12-patient study with combined intramuscular and topical alpha-IFN therapy in the treatment of CIN land II, in HPV+women. The administration of intramuscular doses of up to 3 MIU daily IFN for 3 weeks, combined with intravaginal application of an unspecified dose of IFN cream during the last two weeks of treatment, resulted in a complete response in 7 patients, partial response in 4 patients, and no response in 1 patient.
[0010] Syed et al. (1998) (Syed TA, Ahmadpour A. Human leukocyte derived interferon-a in hydrophilic gel for the treatment of intravaginal warts in women: a placebo-controlled, double-blind study. Inti J STD and AIDS 1998;9:769-772) demonstrated that 16 MIU daily dose of a hydrophilic gel of interferon alpha administered intravaginally for 5 consecutive days per week over a 4-week treatment period was significantly more effective than placebo at curing vaginal warts. While these studies show that interferon therapy is effective in treating CIN associated HPV infections as measured by colposcopy confirmed by cytological and histological examination of random biopsies, none of these studies examine the HPV status post therapy.
[0011] US6656499 discloses a composition for administration of an interferon polypeptide comprising diphasic lipid vesicles comprised of a lipid bilayer comprising a phospholipid and a fatty acylated amino acid in an amount of 0.1-5% (e.g. methionine which is listed among the preferred naturally occurring alpha-amino acids), an oil-in-water emulsion and interferon alpha (e.g. interferon alpha-2b) entrapped in the vesicles. The lipid vesicles were prepared with three dosages of interferon alpha: 5 MU, 15 MU and 40 MU. D1 refers to a method of treating human papilloma virus in a subject comprising applying the vesicles to the site of the infection.
[0012] Based on various limitations in these studies, a non-invasive therapy that could reverse the abnormal cytology during the early stages of the disease process and diminish or eradicate HPV presence would provide a significant benefit to the healthcare system and the physical and emotional well-being of many young women.
Summary of the Invention [0013] In one aspect, the invention includes a biphasic lipid vesicle composition for treating cervical dysplasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and methionine, the composition having an interferon-alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition and between 0.01 to 0.5 weight percent L-methionine.
[0014] The composition, which may be in a cream form, contains in particular embodiments, interferon alpha-2b at an specific activity between 1 and 3 MIU human interferon alpha-2b per gram composition and between 0.01 to 0.5 weight percent L-methionine [0015] In another aspect, the invention includes a method of treating cervical dysplasia in the subject by administering the above composition intravaginally to the subject, at a dose of between 1-20 MIU interferon alpha-2b, and repeating the dosing at least 3 days/week, for a period of at least 4 weeks.
[0016] These and other objects and features of the invention will be more fully appreciated when the following detailed description of the invention is read in conjunction with the accompanying drawings.
Brief Description of the Drawings [0017] FIG. 1 is a scanned image of multilamellar lipid vesicles in the composition of the invention, prepared using an anhydrous plastic proliposome gel method; FIG. 2A is a scanned image of multilamellar liposomes prepared using an "anhydrous plastic proliposome-gel" (’melt’ or’fusion’) method. FIG. 2B is a scanned image of multilamellar liposomes the same composition as in 2A, but prepared by a solvent evaporation method. FIG. 3 is a schematic sectional view of a biphasic MLV with a central aqueous emulsion core, and FIG. 4 is an enlarged portion of the MLV of FIG. 3.
Detailed Description of the Invention I. Biphasic Liposome Composition and method of its preparation [0018] The invention relates to a lipid-bilayer or liposome or lipid vesicle composition for use in delivering an interferon, e.g., interferon alpha-2b by transmucosal delivery, e.g., by intravaginal administration, particularly in the treatment of cervical dysplasia.
[0019] A preferred method of preparing a multilamellar lipid vesicle of the invention is as follows. An oil and a consistency enhancer are admixed. Separately, water and a surfactant are admixed. A water-soluble antimicrobial agent, for example methyl paraben or propylparaben, a buffering agent, such as phosphates, and a chelating agent, such as EDTA, can also be dissolved in the water. These are heated gently, say to about 70°C., and then admixed and homogenized with the oil and consistency enhancer. This results in formation of an emulsion with water as the continuous phase and the oil and consistency enhancer as the dispersed phase. It is desirable that the oil droplets shall be less than about 1 μηι, especially less than about 0.5 μηι, in diameter and if necessary the emulsion can be subjected to additional shear or to sonification to reduce the size of the droplets.
[0020] Separately there is prepared an anhydrous proliposome gel by admixing phospholipid, glycolipid and/or cera-mide and a pharmaceutically acceptable hydrophilic solvent, e.g., propylene glycol, and heating them to form a melt. In the melt there may also be incorporated a material to enhance the strength of the lipid bilayers, for example cholesterol, a material to enhance penetration, for example monolauroyllysine and a material to impart a charge to the lipid bilayers, for example stearic acid. A small amount of an antioxidant, for example ascorbyl palmitate, butylated hydroxy toluene or butylated hydroxyanisole can be incorporated in the melt. The aqueous emulsion is added to the melt and the various components are subjected to agitation which results in formation of the desired multilamellar lipid vesicles having in the central core compartment an aqueous emulsion containing the oil and consistency enhancer as the dispersed phase.
[0021] A water-soluble biologically active material, and in particular, human interferon alpha-2b can be incorporated in solution in the aqueous phase of the emulsion, as discussed below. The interferon alpha-2b is incorporated at into the aqueous phase to form a final composition having a specific activity of between 1-10 MIU per gram composition. The composition is also formulated to contain between 0.01 to 0.5 weight percent of L-methionine, e.g., 0.01-0.2 weight percent L-methionine, and this component may also be incorporated into the aqueous phase at a concentration effective to give the desired concentration in the final composition, and a chelating agent such as EDTA or an antioxidant such as L-methionine and/or a protein stabilizer such as glycine. A. Formation of an anhydrous plastic proliposome gel [0022] A liposome-forming component and other necessary excipients are melted with a pharmaceutically acceptable hydrophilic solvent, such as propylene glycol.
[0023] The expression "liposome-forming component" designates the substance or substances used as major component of the lipid bilayers. Typical liposome-forming components include glycolipids, lecithins, phospholipids, ceramides or mixtures thereof which are used as a primary ingredient in the formation of the lipid bilayer. However, other natural and synthetic compounds having the required amphipatic character can be incorporated with the phospholipid, glycolipid orceramide, replacing some of these expensive materials, provided that the essential character of the lipid bilayers is not adversely affected. The choice of the appropriate materials is within the knowledge of the person skilled in the art. Examples include phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phos-phatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid and the cerebrosides, ether lipids and phytanols.
[0024] The liposomal formulations of the present invention preferably contain saturated and/or unsaturated phospholipids, more preferably phosphatidylcholine, lysophosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, glycolipids and ceramides. The phospholipids are preferably in combination with a penetration enhancing agent such as monolauroyllysine, dipalmitoyllysine or methyl salicylate to achieve predominantly transdermal delivery potential.
[0025] A "fatty substance" can be used to enhance the strength of the lipid bilayers. Examples of useful fatty substances include steroids such as cholesterol, coprostanol, cholestanol and cholestane and long chain fatty acids (C16 to C22), especially saturated ones such as stearic acid. In addition to enhancing strength of the lipid bilayer, acids impart a negative charge. Saturated or unsaturated acids can be used. Other fatty substances that can be used include C16 to C22 fatty amines, fatty acylated proteins, fatty acylated peptides, fatty acylated PEG and derivatives. These fatty substances are incorporated with the abovementioned liposome-forming components and improve physical stability and appearance of the product.
[0026] The hydrophilic solvent is used as a plasticizer of the liposome-forming component and an aid to prepare a uniform melt. Examples of hydrophilic solvents include but are not restricted to propylene glycol, glycerol, polyethylene glycol having a molecular weight ranging between 300 and 8000, ethanol, and mixtures thereof. The resulting melt can be described as being an anhydrous plastic proliposome gel. This anhydrous plastic proliposome gel contains all the lipid phase ingredients and can be prepared and stored in advance in large quantities. It is a semisolid material with a homogenous consistency. B. Formation of the multilamellar lipid vesicles [0027] Hydrophilic ingredients such as penetration enhancers, preservatives and the like, are prepared separately as an aqueous solution, which forms the continuous phase of an emulsion. This is added to the lipid phase melt, previously heated to the appropriate melting temperature that can range from 40°C. to 80°C., and vigorously mixed by any given technique which allows the achievement of the desired product size. Examples of mixing techniques include vortexing or propeller mixing. At this stage, it is also possible to incorporate (dissolve) solid biologically active agents that will be entrapped within the lipid bilayers.
[0028] This procedure is suitable for the preparation of various amounts of topical liposomal product. If vortex mixing is used as the agitation, up to about 20 g of the product can be prepared. If a laboratory scale propeller mixer is used, up to about 2 Kg to 10 Kg of the product can be made. This formulation procedure can also be adapted for large scale manufacturing. Hence, the propeller mixing technique can be directly scaled up by geometrically increasing the size of the vessel and the diameter of the propeller mixer. However, as the vessel size increases, the preferred set up would be a combination mixer i.e a high intensity mixer with propeller mixer and a scraped surface agitator. The aqueous phase can either be pumped from tank A to tank B containing the anhydrous plastic proliposome gel or the aqueous phase can be mixed with the emulsion prior to adding to Tank B at the required temperature and mixed. This procedure is suitable for the production of any topical liposomal product on a large scale.
[0029] Liposomal compositions can be prepared with the multilamellar lipid vesicles of the present invention by using appropriate pharmaceutical additives. For example, it might be required to add viscosity increasing agents to the final liposome preparation. The addition of other pharmaceutically acceptable compounds is within the purview of the person skilled in the art. C. Characteristics of the final multilamellar lipid vesicle product [0030] A schematic representation of a multilamellar lipid vesicle prepared in accordance with the process described above is shown at FIG. 3. The multilamellar lipid vesicle, generally designated by reference numeral 2, is made of a series of spaced apart lipid bilayers 4, 6 and 8 which define a series of peripheral aqueous solution compartments 3 and 5. The smallest lipid bilayer 7 defines in its center a central core compartment 9. Although only 6 lipid bilayers are shown, it should be appreciated that the figure is simplified and schematic and in fact many more than 6 lipid bilayers are present.
[0031] FIG. 4 is an enlargement of the vesicle of FIG. 3 showing in more detail the central core compartment and parts of some of the lipid bilayers. The central core compartment 9 is occupied by an aqueous emulsion composed of water 10 as continuous phase and lipophilic droplets or fine solid particles 11 as dispersed phase. The lipophilic droplets or fine solid particles are surrounded by a layer of surfactant molecules 12, the hydrophilic portions 13 of each surfactant molecule extending into the aqueous phase and the hydrophobic portions being at the surface of the oil droplets.
[0032] Surrounding the core compartment is the innermost lipid bilayer 15. The lipid bilayer is composed of two layers of lipid molecules 16. Each lipid molecule 16 in a layer is oriented substantially parallel to adjacent lipid bilayers, and two layers that form a bilayer have the polar ends 17 of their molecules exposed to the aqueous phase and the nonpolar ends 18 adjacent to each other. Between the innermost lipid bilayer 15 and the next innermost lipid bilayer 19 is a peripheral compartment 20 that is filled either with water or with the aqueous emulsion. As shown, surfactant surrounded lipophilic droplets or particles 11 can be present in the peripheral compartment 20.
[0033] Surrounding the peripheral compartment 20 is the next innermost lipid bilayer 19, which is in turn surrounded by a further peripheral compartment and a further lipid bilayer.
[0034] It will be appreciated that biologically active ingredient, e.g., interferon alpha-2b, and the L-methionine component will be present in the water of the aqueous emulsion in the central core compartment 9 and in the peripheral compartments 20. Biologically active ingredients that are lipophilic, such as consistency enhancers or uptake enhancers, can be present in the dispersed phase of the emulsion in the central compartment 9 and in the peripheral compartments 20. They can also be present in the interior of the lipid bilayers as shown at 21. The biologically active ingredient can constitute the lipophilic droplets 21, or the biologically active ingredient can be dissolved in a lipophilic solvent that forms droplets 21. Thus the invention permits the topical application of biologically active ingredients that are water-soluble or water-insoluble.
[0035] The composition is preferably formed under conditions in which at least about 30 weight percent, and preferably between about 40 and 70 weight percent of these aqueous components is present in liposome entrapped form, as opposed to being carried in the extra-vesicular bulk phase of the composition. These levels of entrapment can be achieved by various known strategies, e.g., forming the lipsomes by a reverse-phase evaporation method and/or encapsulating the aqueous phase material at a high concentration of liposome-forming lipids, thus minimizing the amount of bulk aqueous phase.
[0036] FIG. 1 is a scanned image, magnified 440X of vesicles made for use as a topical lotion. This product displayed the consistency of a lotion or semi-solid cream. Inspection of the scanned image reveals multilamellar structures with uniform size distribution. These have displayed physical stability for extended periods of time of more than one year.
[0037] In order to demonstrate the difference in properties observed in the liposome population produced in accordance with the preferred method of the present invention, comparative tests were conducted between two liposome compositions prepared from the same ingredients but using in one case the solvent evaporation method and in the other case the preferred anhydrous plastic proliposome gel method. FIG. 2A is a scanned image of the liposome population prepared using the anhydrous proliposome gel (’melt’ or’fusion’) method and FIG. 2B is a scanned image of the liposome population prepared using the solvent evaporation method. As can be seen, the liposome population obtained using the anhydrous plastic proliposome gel method has a liposome size distribution which is substantially more uniform than that obtained using the solvent evaporation method. Also, minimal amounts of aggregated or fused liposomes are formed when using the anhydrous plastic proliposome gel method, whereas large aggregates can be observed in the liposome population obtained using the solvent evaporation method.
[0038] In some embodiments of the invention the lipophilic substance is an oil or solid/semisolid lipophilic consistency enhancer which can be encapsulated into liposomes. As solid or semisolid lipophilic consistency enhancers there are mentioned fatty alcohols, waxes, fatty alcohol fatty acid esters, glyceride esters, white petrolatum and mixtures thereof. Examples of oils which have successfully been encapsulated into liposomes pentaerythritol tetracaprylate/caprate, pen- taerythritol tetraisostearate, cetearyl octanoateand canola oil, jojoba oil, peanut oil, rice bran oil, cottonseed oil, sunflower oil, corn oil, walnut oil, avocado oil, peru balsam, clove oil and eugenol. Plant extracts based on oil have also been successfully incorporated into liposomes. Solid/semi solid lipophilic consistency enhancer ingredients can be selected from waxes, fatty alcohols, fatty acid esters, glyceryl stearate, petrolatum or combinations thereof. Specific examples of preferred consistency enhancers include beeswax, glyceryl tribehenate, glyceryl stearate, stearyl heptanoate, stearyl palmitate, cetyl alcohol, stearyl alcohol, myristyl myristate, behenyl erucate and cetyl palmitate.
[0039] The viscosity of a composition of vesicles in accordance with the invention and containing a consistency enhancer is greater than the viscosity of corresponding vesicles that do not include a consistency enhancer but are otherwise identical. By varying the amount of consistency enhancer it is possible to achieve virtually any required viscosity, from a relatively mobile liquid, to a "lotion", to "creamy’ to "thick cream". Determination of amounts of consistency enhancer to achieve a particular viscosity of the composition can be determined by routine experiment.
[0040] The surfactant used to coat the oil droplet or the solid/semisolid lipophilic consistency enhancer ingredients is important for the successful encapsulation of a lipophilic core into multilamellar lipid vesicles. About 30 different types of surfactants were screened and primary cationic emulsifiers were found to give the most acceptable results. The most preferred surfactant is benzalkonium chloride. Nonionic or amphoteric surfactants can also be used, such as naturally derived emulsifiers: PEG-60 almond glycerides, avocado oil diethanolamine, ethoxylated jojoba oil (PEG-40 Jojoba acid and PEG-40 Jojoba alcohol); polyoxyethylene derivatives: polyoxyethylene (20) sorbitan monooleate, polyoxyethylene (20) sorbitan monostearate; lanolin derivatives: polychol 20 (Laneth 20), polychol 40 (laneth 40); neutral phosphate esters: PPG-cetyl ether phosphate, DEAoleth-3 phosphate. It is also possible to use anionic surfactants such asacylgluta-mates: TEA-cocoyl glutamate, sodium lauroyl glutamate, sodium hydrogenated tallow glutamate and sodium cocoyl glutamate. It is desirable that the surfactant has a high critical micellar concentration (CMC).
[0041] When preparing the lipophilic substance-in-water emulsion, the hydrophilic ingredients and surfactants are all incorporated in water. Once the water phase of the emulsion has been prepared, the oil and/or solid/semisolid lipophilic ingredients are added to the water in a homogenizerfor a period of time ranging from 5 to 30 minutes to obtain relatively small droplet size. Preferred droplet size ranges from 0.1 urn to 1 urn, most preferably below about 0.5 urn. The lipid phase melt is then heated and the lipophilic substance-in-water emulsion is added and vigorously mixed by either vortexing or propeller mixing depending on the product size.
[0042] The formulation procedure described above can be easily adopted for large scale manufacturing. The propeller mixing approach can be directly scaled up by geometrically increasing the size of the vessel and the diameter of the propeller mixer. However, as the vessel size increases, a preferred set up might be a combination mixer such as a high intensity mixer with propeller mixer and a scraped surface agitator. In a large scale operation, the lipophilic substance-in-water emulsion can be pumped from a first tank into a second tank containing the anhydrous plastic proliposome gel at the required temperature and mixed.
[0043] With the multilamellar lipid vesicle of the present invention, oil droplets containing solubilized lipophilic biologically active compounds or oily plant extracts can be delivered through liposome encapsulation. Furthermore, the possibility of multicompartment encapsulation provides drug release over extended periods of time. Also, encapsulation of lipophilic solid/semisolid consistency enhancers into the central lipophilic core compartment provides enhanced viscosity to the final liposome composition. In this case, the addition of viscosity-increasing agents in the final liposome preparation can be avoided.
[0044] Overall, the preparation of multilamellar lipid vesicles with a central emulsion core component provides a physically stable, uniform liposome composition. The composition has a viscosity that is suitable for topical administration and can be easily manufactured on a large scale. D. Exemplary IFN-alPha-2b cream formulation for intravaginal use [0045] Table 1 gives the components in one exemplary lipid-bilayer composition formed in accordance with the invention, where the amount of each component is expressed in units of mg/g final composition, and given in both ranges and exemplary quantities (parentheses). The resulting composition is referred to in the studies below as "Formulation Q25C", and is formed as detailed below.
Table 1
(continued)
Description of the Manufacturing Process for Q25C
[0046] Step 1. Preparation of oil-in-water microemulsion: Olive oil, glycerol monostearate 40-55 Type I, cetyl alcohol and butylated hydroxy toluene are melted together at 75°C ± 5°C. The aqueous component of the emulsion including purified water, PEG-40 castor oil hydrogenated, benzalkonium chloride 50% solution, methylparaben, propylparaben, L-methionine, edetate disodium dihydrate, and phosphates are heated together in a stainless steel vessel at 75°C ± 5°C while stirring until the ingredients are dissolved. The oil component (75°C ± 5°C) is then added to the aqueous component (75°C ± 5°C) gradually, while mixing to form a coarse emulsion. Coarse emulsion is then homogenized by processing through a Microfluidizer until a homogeneous emulsion is formed. This microemulsion is cooled down to 8°C - 12°C.
[0047] Step 2: Preparation of the Lipid Phase: The Lipid Phase is prepared by melting Phospholipon 90H, cholesterol and butylated hydroxy toluene with propylene glycol in a MMU 10 mixer by heating to about 80-90°C while mixing at a slow speed. The mixing and heating of the Lipid Phase ingredients is continued until a clear melt is formed which is then cooled to about 60°C.
[0048] Step 3: Preparation of the Aqueous Phase: The required quantity of IFN alpha-2b stock solution is added and mixed gently with a mixture of L-methionine, glycine and purified water.
[0049] Step 4: Product Formulation: The Aqueous Phase containing interferon alpha-2b (from Step 3) is added to the System A (from Step 1) in a stainless steel jacketed mixing tank. This mixture is maintained between 8°C - 12°C while the mixture is mixed slowly and purged with nitrogen gas. The cooled mixture of System A-Aqueous Phase is rapidly added to the Lipid Phase which is being mixed at high speed in the MMU10 mixer. Mixing proceeds for 10-15 minutes while the temperature of the mixture is maintained about 57-60°C. The bulk product thus formed is slowly mixed and cooled to 19°C - 25°C in a MMU 10 mixer. The product is transferred from the MMU 10 mixer into a 10 L stainless steel storage vessel and purged with nitrogen gas. The bulk product is filled into 1g polypropylene tubes using a Unipac 100 Filler. The tubes are purged with nitrogen and then the required amount of the product is filled into the tubes, which are thermally sealed. The filled tubes of Interferon alpha-2b Cream are stored at 5°C ± 3°C.
II. Preclinical and clinical studies on efficacy against LSIL A. Study Rationale [0050] At present, there is no immediate therapy available for women with HPV presenting with LSIL. Interferon is known to be active against a variety of HPV-induced lesions, particularly cutaneous lesions, such as genital warts. A therapy that could treat early stage cervical HPV infections would provide a significant benefit to and the physical and emotional well-being of many young women.
B. Summary of Pre-Clinical Studies with Q25C
[0051] Toxicology studies conducted in support of the present invention were conducted in compliance with the requirements of "Good Laboratory Practice for Nonclinical Laboratory Studies" and OECD Principles of Good Laboratory Practice. The following three types of toxicology studies were carried out: [0052] Skin sensitisation of Topical Interferon Alpha-2b Cream in guinea pigs (Buehler Method).
[0053] Repeated dose dermal irritation study of Topical Biphasix Interferon Alpha-2b Cream in rabbits.
[0054] Vaginal irritation study of Interferon Alpha-2b Cream in rabbits.
[0055] Apart from the 3 above mentioned toxicology studies the following should betaken into account for the toxicology profile for I FN-alpha-2b composition of the invention: The active drug substance, interferon alpha-2b, is widely considered a safe drug therapy as marketed world-wide by Helix’s supplier of drug substance, Schering Plough (Intron A®).
[0056] Schering Plough has already completed extensive toxicology profiling with interferon alpha-2b in multiple species.
[0057] The patent owner performed the clinical trial described herein such that daily and total interferon alpha-2b administration to patients did not exceed published safety limits.
[0058] The components making up the composition are all quality, recognized ingredients.
[0059] The pre-clinical profiling has included two formulations of Interferon alpha-2b Cream designated "Formulation Q25C" whose composition and method of preparation are described above. B1. Skin sensitization studies [0060] A 10-day exploratory study was performed in which Formulation Q25C was applied twice daily to sites on shaven skin of the dorsal aspect of New Zealand Albino rabbits at a concentration of 2 MIL) interferon alpha-2b per gram of cream (1x the proposed clinical concentration). Test sites were cleaned in between applications using the moistened gauze technique described above to remove any residual cream from previous applications. Study controls included a negative control (saline) and a vehicle control (identical in composition to Formulation Q25C, minus interferon alpha-2b replaced with additional Purified Water).
[0061] The appearance of skin sites was rated and scored for signs of erythema and oedema daily using the standard Draize scoring system. In addition, animals were observed daily for any sign of systemic toxicity. No necropsy assessments were performed at the end of the study.
[0062] Through the course of this exploratory study, findings for erythema were generally good, (Draize scores for redness of generally 2), and only very slight or slight oedema (score of 1-2) was observed. Most notably, skin fissures present on intact surfaces were apparent in one animal only. No signs of systemic toxicity were observed. C. Vaginal Irritation studies [0063] Formulation Q25A was administered intravaginally daily for 5 consecutive days/week for 6 weeks at concentrations of 2 MIU and 20 MIL) interferon alpha-2b per gram of cream (1x and 10x the proposed clinical concentration). Study controls included a negative control (saline) and a vehicle control minus interferon (alpha-2b replaced with additional Purified Water).
[0064] The appearance of the vaginal opening and perineum was rated for signs of erythema, oedema and vaginal discharge daily. In addition animals were observed daily for any signs of systemic toxicity, and sacrificed at the end of the study to determine any signs of gross pathology.
[0065] The rabbits did not show evidence of systemic toxicity or vaginal irritation based on in-life observations of the vaginal opening and perineum during the study. At necropsy, no gross pathological findings were noted in tissues/organs (including vagina). Based on the histopathology grading, the cream was classified as a minimal irritant.
[0066] Minimal to mild vaginal epithelial hyperplasia, metaplasia and large vacuolation of the epithelium or lamina propria were observed in several animals to whom vehicle control cream was administered and in 1 saline control animal. Hyperplasia and metaplasia may represent minimal to mild adaptive epithelial responses to repeated daily administration of the vehical cream over the 6-week study duration. There was no vaginal epithelial necrosis, erosion or ulceration present in any animals.
Conclusions from Toxicology Studies To-Date [0067] The above studies support the conclusion that the composition of the present invention, as embodied in Formulation Q25C, is non-sensitizing, and at worst, a mild to moderate irritant for a transient period initially and, thereafter, only mildly irritating, if at all, through the 30-day period studied. D. Clinical Studies [0068] The composition of the present invention, as embodied in the Q25C Formulation, was tested for clinical efficacy and side effects in the treatment of LSIL with FIPV status, (Low-Grade Squamous Intraepithelial Lesion with human papaloma virus status), where "intraepithelial" means abnormal cells are only present in the surface layer of the cervix. The objective of the study was to determine efficacy and safety of the application of topical Interferon alpha-2b Cream Q25C compared with a second study performed as a control population to describe the natural history of disease progression or regression. The methodology and clinical study, number of subject studies, and the clinical endpoints are presented in Table 2, and the criteria for evaluation, in Table 3.
Table 2: Clinical Trial summary: Low dose interferon alpha cream for the treatment of cytologically confirmed LSIL with FIPV status
(continued)
Table 3
(continued)
[0069] Efficacy parameters: Inferential statistical analysis of the efficacy parameters was purely explorative, using a=0.05 for each test carried out without a- adjustment for multiple testing. The difference in response rates between both groups was determined with the Chi2-test.
[0070] The main study outcome was based on the Pap- response rate as compared between the two study populations. Pap smear normalization was considered to occur if the patient’s Pap smear improved to group II or better from any of Pap smear groups IIW through HID as per the common European or "Munich Classification" system of LSIL cytology.
[0071] Safety parameters: All analyses were of descriptive nature. Laboratory parameters were analyzed by means of the asymptotic Mann-Whitney-U-test (between groups differences) and the asymptotic Wilcoxon- test for dependent samples (within group differences). All AEs were coded according to MedDRA and listed completely and separately by study groups. An AE related and a patient related analysis was performed. · Primary endpoint (ITT): 8 out of 20 patients (40.00%) in the treatment- group were responders compared to 3 out of 21 patients (14.29%) in the control-group. However, Pap smear results of two patients of the treatment group worsened after a preliminary PAP- response at earlier visits. Thus, if one considers PAP- response after the 12 weeks observation period only (as by definition in the control group), 6 out of 20 patients (30.00%) of the treatment group were responders.
[0072] PAP- response in the Per Protocol population (PP: In the treatment-group 7 out of 15 patients (46.67%) were responders compared to 3 out of 19 patients (15.79%) in the control- group. If one considers PAP- response after the 12 weeks observation period only • Adverse events: 36 AEs were documented. 34 AEs in the treatment- group: 7 of these onset before start of treatment. Two SAEs were observed in 1 patient of the control group. AE analyses were based on the 27 AEs of the treatment group which started after start of treatment (’treatment emergent AEs’); these 27 AEs occurred in 14 of 20 patients (70.00%) of the treatment- group. According to MedDRA- primary terms 3 AEs came from the category ’Metrorrhagia’ and 4 from the category ’Headache’; all other AEs- classes occurred only once or twice. 5 SAEs in 3 patients all without any causal relationship related to treatment occurred under study medication (treatment group: pregnancy before start of treatment in 1 patient, accident during swimming with concussion of the brain and compression of the cervical spine in 1 patient; control group: pregnancy with abortion in 1 patient). There were no deaths and no other significant AEs. • Laboratory: Urine: No significant change over time was observed with respect to urine-pH- values. In one center, some urine parameters were determined quantitatively: while there was a clear increase of mean erythrocytes, prepost-changes were small and not significantfor this and the other parameters. In some patients qualitative determined leucocytes, nitrate, protein, urobilinogen, bilirubin and/or blood were found in urine. Blood: Significant between group differences were found with respect to hematocrit, MCV, MCHC, thrombocytes and basophils at start and end of the study, not, however, with respect to the mean pre-post- changes. There seems to be a tendency for an increase in leucocytes (however, notsignificant), lymphocytes [Gpt/I] (significant), monocytes [Gpt/I] (significant) and basophils [Gpt/I] (significant) in the treatment group patients. Significant between group differences were found with respect to creatinine, ASAT and alkaline phosphatase (AP) at start and end of the study, not, however, with respect to the mean pre-post- changes. There was a significant mean decrease with respect to bilirubin in both groups, and a significant mean increase with respect to ALAT in the control group. For all lab parameters addressed in the CRF, the Investigator’s assessment (normal, if outside normal range: clinically relevant or clinically irrelevant) was required. Clinically relevance was documented in a rare number of cases only.
[0073] Physical examination and vital signs: Only in one case from the treatment- group a pathological finding was observed at visit V06 (angina). Within each study group, the vital signs remained nearly constant during the trial within the limits of normal fluctuation and measurement errors. There was a significant difference between groups (U-tests) with respect to diastolic blood pressure and heart rate at visit V01 with higher values in the treatment- group, but no significant difference with respect to the pre-post- differences.
[0074] Overall the treatment arm has a higher response rate than the untreated compare group. Statistic significance using a=0.05 is not met for the primary endpoint if compared directly. However, the small sample size and the fact the studies were conducted separately and independently with slightly different colposcopic examination schedules make this type of comparison difficult.
[0075] Additional Efficacy Results: A subgroup analysis of the PAP Hid presenting patients revealed a significant difference between treatment groups. 6 of the 14 PAP Hid patients from the ITT-population of study IFN002 were responders compared to no responder in the 14 PAP Hid patients from the PP-population.
[0076] Beyond the PAP- response rate parameter, the colposcopic diagnosis was statistically significantly better in the treatment group compared to the control group at the time of individual final observation. In study IFN 002,12 patients (60%) improved towards ’normal’ or atypical’. By comparison, in the non-interventional study, only 2 patients (9.52%) improved at the time of individual final observation.
Claims 1. A biphasic lipid vesicle composition for use in the treatment of cervical dysplasia by intravaginal delivery, comprising a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1 and 10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. 2. The composition for use of claim 1, which is in a cream form. 3. The composition for use of claim 1, which has an interferon alpha-2b specific activity of between 1 and 3 MIL) human interferon alpha-2b per gram composition. 4. The composition for use of claim 3, which contains between 0.01 to 0.5 weight percent L-methionine. 5. The composition for use of claim 1, wherein at least 30% of the interferon alpha-2b and L-methionine in the composition are present in the entrapped oil-in-water emulsion. 6. The composition for use of claim 1, whereby the suspension is to be administered intravaginally to the subject, at a dose between 1 and 20 million international units (MIU) of interferon alpha-2b, and said administering is to be repeated at least 3 days/week, for a period of at least 4 weeks. 7. The composition for use of claim 6, which has a specific activity between 1 and 3 MIU human interferon alpha-2b per gram composition. 8. The composition for use of claim 6, which is in cream form, and is to be administered at a dose of between 3-7 g per administration. 9. The composition for use of claim 6, which contains between 0.01 to 0.5 weight percent L-methionine. 10. The composition for use of claim 6, wherein at least 30% of the interferon alpha-2b and L-methionine in the composition to be administered are present in the entrapped oil-in-water emulsion. 11. The composition for use of claim 6, wherein said administering is to be repeated at least 3 days/week, for a period of at least 6 weeks. 12. A method of preparing a biphasic vesicle composition comprising a multilamellar lipid vesicle which comprises: (a) providing an aqueous emulsion phase comprising water and a surfactant, and human interferon alpha-2b and 0.01 to 0.5 weight percent of L-methionine incorporated in the emulsion, wherein the aqueous phase further comprises an additional antioxidant, a chelating agent, and/or a protein stabilizer; and (b) admixing the aqueous emulsion phase with a dispersed phase comprising an oil and consistency enhancer such that the dispersed phase is dispersed in the aqueous emulsion phase; wherein the composition has a human interferon alpha-2b activity of between about 1 and 10 MIU per gram composition. 13. The method of claim 12, wherein said dispersed phase is comprised of oil droplets having a size of less than 1 μηι. 14. The method of claim 12 or claim 13, wherein said multilamellar vesicle comprises cholesterol.
Patentansprüche 1. Zweiphasige Lipidvesikelzusammensetzung zur Verwendung bei der Behandlung von Zervixdysplasie mittels intravaginaler Verabreichung, umfassend eine Suspension von Lipid-Doppelschicht-Vesikeln, in die eine Öl-in-Was-ser-Emulsion, humanes Interferon alpha-2b und L-Methionin eingeschlossen ist, wobei die Zusammensetzung eine für Interferon alpha-2b spezifische Aktivität zwischen ungefähr 1 und 10 MIU (Millionen internationale Einheiten) pro Gramm Zusammensetzung und zwischen 0,01 und 0,5 Gewichtsprozent L-Methionin aufweist. 2. Zusammensetzung zur Verwendung aus Anspruch 1, die in der Form einer Creme ist. 3. Zusammensetzung zur Verwendung aus Anspruch 1, die eine für Interferon alpha-2b spezifische Aktivität zwischen 1 und 3 MIU humanem Interferon alpha-2b pro Gramm Zusammensetzung aufweist. 4. Zusammensetzung zur Verwendung aus Anspruch 3, die zwischen 0,01 und 0,5 Gewichtsprozent L-Methionin enthält. 5. Zusammensetzung zur Verwendung aus Anspruch 1, wobei mindestens 30 % von dem Interferon alpha-2b und L-Methionin in der Zusammensetzung in der eingeschlossenen ÖI-in-Wasser-Emulsion vorhanden sind. 6. Zusammensetzung zur Verwendung aus Anspruch 1, wobei die Suspension dem Subjekt intravaginal zu verabreichen ist, bei einer Dosis zwischen 1 und 20 Millionen internationalen Einheiten (MIU) Interferon alpha-2b, und wobei die Verabreichung an mindestens 3 Tagen/Woche zu wiederholen ist, über einen Zeitraum von mindestens 4 Wochen. 7. Zusammensetzung zur Verwendung aus Anspruch 6, die eine spezifische Aktivität zwischen 1 und 3 MIU humanem Interferon alpha-2b pro Gramm Zusammensetzung aufweist. 8. Zusammensetzung zur Verwendung aus Anspruch 6, die in der Form einer Creme ist, und bei einer Dosis zwischen 3-7 g pro Verabreichung zu verabreichen ist. 9. Zusammensetzung zur Verwendung aus Anspruch 6, die zwischen 0,01 und 0,5 Gewichtsprozent L-Methionin enthält. 10. Zusammensetzung zur Verwendung aus Anspruch 6, wobei mindestens 30 % von dem Interferon alpha-2b und L-Methionin in der zu verabreichenden Zusammensetzung in der eingeschlossenen ÖI-in-Wasser-Emulsion vorhanden sind. 11. Zusammensetzung zur Verwendung aus Anspruch 6, wobei die Verabreichung an mindestens 3 Tagen/Woche zu wiederholen ist, über einen Zeitraum von mindestens 6 Wochen. 12. Verfahren zum Fierstellen einer zweiphasigen Vesikelzusammensetzung, die ein multilamellares Lipidvesikel umfasst, umfassend: (a) Bereitstellen einer wässrigen Emulsionsphase, die Wasser und ein Tensid umfasst, und humanes Interferon alpha-2b und 0,01 bis 0,5 Gewichtsprozent L-Methionin, eingeschlossen in der Emulsion, wobei die wässrige Phase weiterein zusätzliches Antioxidans, einen Chelatbildner und/oder einen Proteinstabilisator umfasst; und (b) Vermischen der wässrigen Emulsionsphase mit einer dispergierten Phase, umfassend einen Öl- und Konsistenzgeber, sodass die dispergierte Phase in der wässrigen Emulsionsphase dispergiert wird; wobei die Zusammensetzung eine Aktivität des humanen Interferon alpha-2b zwischen ungefähr 1 und 10 MIU pro Gramm Zusammensetzung aufweist. 13. Verfahren nach Anspruch 12, wobei die dispergierte Phase aus Öltropfen mit einer Größe von weniger als 1 μηι besteht. 14. Verfahren nach Anspruch 12 oder Anspruch 13, wobei das multilamellare Vesikel Cholesterin umfasst.
Revendications 1. Composition de vésicules lipidiques biphasiques destinée au traitement d’une dysplasie du col de l’utérus par administration intravaginale, comprenant une suspension de vésicules à deux couches lipidiques dans lesquelles sont piégés, une émulsion d’huile-dans-l’eau, l’interféron alpha-2b humain et la L-méthionine, la composition présentant une activité spécifique interféron alpha-2b comprise entre environ 1 et 10 MUI (million d’unités internationales) par gramme de composition, et entre 0,01 et 0,5 pour cent en poids de L-méthionine. 2. Composition selon la revendication 1, qui se présente sous la forme d’une crème. 3. Composition selon la revendication 1, qui présente une activité spécifique interféron alpha-2b comprise entre 1 et 3 MUI d’interféron alpha-2b humain par gramme de composition. 4. Composition selon la revendication 3, qui contient entre 0,01 et 0,5 pour cent en poids de L-méthionine. 5. Composition selon la revendication 1, dans laquelle au moins 30 % de l’interféron alpha-2b et de la L-méthionine de la composition sont présents dans l’émulsion d’huile-dans-l’eau piégée. 6. Composition selon la revendication 1, dans laquelle la suspension doit être administrée par voie intravaginale au sujet, à une dose comprise entre 1 et 20 MUI (million d’unités internationales) d’interféron alpha-2b, et ladite administration doit être répétée au moins 3 jours par semaine pendant une période d’au moins 4 semaines. 7. Composition selon la revendication 6, qui présente une activité spécifique comprise entre 1 et 3 MUI d’interféron alpha-2b humain par gramme de composition. 8. Composition selon la revendication 6, qui se présente sous la forme d’une crème et qui doit être administrée à une dose comprise entre 3 et 7 g par administration. 9. Composition selon la revendication 6, qui contient entre 0,01 et 0,5 pour cent en poids de L-méthionine. 10. Composition selon la revendication 6, dans laquelle au moins 30 % de l’interféron alpha-2b et de la L-méthionine de la composition à administrer sont présents dans l’émulsion d’huile-dans-l’eau piégée. 11. Composition selon la revendication 6, dans laquelle ladite administration doit être répétée au moins 3 jours par semaine pendant une période d’au moins 6 semaines. 12. Procédé de préparation d’une composition de vésicules biphasiques comprenant une vésicule lipidique multilamel-laire qui comprend les étapes consistant à : (a) fournir une phase d’émulsion aqueuse comprenant de l’eau et un tensioactif, et un interféron alpha-2b humain et 0,01 à 0,5 pour cent en poids de L-méthionine incorporés dans l’émulsion, dans laquelle la phase aqueuse comprend en outre un antioxydant supplémentaire, un agent de chélation et/ou un stabilisant protéique ; et (b) mélanger la phase d’émulsion aqueuse avec une phase dispersée comprenant un agent améliorant l’uniformité lipidique tel que la phase dispersée se disperse dans la phase d’émulsion aqueuse ; dans laquelle la composition présente une activité interféron alpha-2b humain comprise entre environ 1 et 10 MUI par gramme de composition. 13. Procédé selon la revendication 12, dans lequel ladite phase dispersée est constituée de gouttelettes d’huile ayant une dimension inférieure à 1 μπι. 14. Procédé selon la revendication 12 ou 13, dans lequel ladite vésicule multilamellaire comprend du cholestérol.
REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.
Patent documents cited in the description • US 6656499 B [0011]
Non-patent literature cited in the description • JONES, BA ; DAVEY DD. Quality management in · SCHNEIDER A; GRUBERT T ; KIRCHMAYR R ; gynaecologic cytology using interlaboratory compar- WAGNER D ; PAPENDICK U ; SCHLUNCK G. Ef- ison. Arch Pathol Lab Med, 2000, vol. 124(5), 672-81 ficacy trial of topically administered Interferon gam- [0002] ma-1 bgelincomparisontolasertreatmentincervical • OSTOR AG. Natural history of cervical intraepithelial intraepithelial neoplasia. Arch Gynecol Obstet, 1995, neoplasia: a critical review. Int. J. Gynecol Pathol, vol. 256, 75-83 [0008] 1993, vol. 12, 186-92 [0003] · ARCONE R.; BELLINI P.; CARDONE G.; CAR- • PENNA C ; FALLAN MG ; GORDIGIANI R et al. In- DONE A. Treatment of cervix condylomata with al- tralesional beta-interferon treatment of cervical in- pha-IFN leucocytar. Clin Exp ObstGyn, 1995, vol. 22 traepithelial neoplasia associated with human papil- (4), 326-9 [0009] lomavirus infection. Tumori, 1994, vol. 80, 146-150 · SYED TA ; AHMADPOUR A. Human leukocyte de- [0007] rived interferon-a in hydrophilic gel for the treatment • KATESMARK M.; COULTER SMITH S.; REY- of intravaginal warts in women: a placebo-controlled, NOLDS K.; LAWTON F. A pilot study of the efficacy double-blind study. Inti J STD and AIDS, 1998, vol. and tolderability of intralesional recombinant human 9, 769-772 [0010] beta interferons in cervical intraepithelial neoplasia.
Ann Acad Singapore, 1999, vol. 28 (6), 775-7 [0007]
Claims (5)
- KÉTFÁZISÚ UFIDVEÖKULUM KÉSZÍTMÉNY ÉS ELJÁRÁS OERVIKÁUS DíSZPLÁZiA KEZELÉSÉRE JNTRAVAGINÁUS ADAGOLÁSSAL l&afoaáilmi !|ipfptn:|öik:: 1 Kétfázisú ilpkivezíkuíum készítmény cervikáiís díszplázía Mfiililápap intravagínáils adagolással történő alkalmazásra, amely tartalmazza ffpiclléttisritages vezikulumok szuszpenzsöját a yezíkuíymökba hm van zárva oíaya^zben, emulzió, humán Interteron-aiíaJíb és L-metionin, a készítmény specifikus lhtértáíőmaifa-'2h-akÍálÍiSr a készítmény 1 grammjára vonatkoztatva körűíbélöi 1 - 10 !*1IU (millió nérhzitkőzi egység), és a készítmény 0,01 - öt5 iömeg% L-matlonint tartalmaz. $. A készítmény alkalmazásra az 1. igénypont szerint, amely kréf?r;%rrni|á,
- 3. A készítmény alkalmazásra az 1. Igénypont szerint, amelynek specifikus sntarfemft"aífa>'2h-akfMtása a készítmény 1 grammjára voniÉuztatya 1 - 3 ytü humán mterferon-alfa-2b.
- 4. A készítmény alkalmazásra a 3. igénypont szerint, amely 03)1 torneg% L -metionint tarta imaz. i, A készítmény alkalmazásra az 1 igénypont szennt. ahol a készftmánybön lévő interferonmlfa^h-nek es l-metiorunnak féyaíáhb & ;:bá^áít:.étó|^ · vtzberr emulatiban van jelem Is A készítmény alkalmazásra m 1 Igénypont szedni, ahol a szusipanzié inlr&vaglnáíssan adagolandó az alanynak, 1 - 20 millió nemzetközi egység (MIU) intoríeron-alfa-2p döz-sPan. és az adagolás legalább híeteáte· í'iíáPáé végzendő, legalább 4 héten áí. Ά A készrtmény alkalmazásra a 6. igénypont szerint, amelynek specifikus aktytisi i: feftKlMfiy f grammjára vonatkoztatva 1 - 3 rvuu humán $, A készítmény alkalmazásra a Θ Igénypont szánni, amely krém formájú és adagolási alkalmanként 3 - T g dózisban adagolandó. í, A készítmény alkalmazásra a B, igénypont szerint, amely 0,01 - 0,5 tömeg0* L- rrt et Ιο η I η t ta rta I m az.
- 10. A készítmény alkalmazásra a 6, Igénypont szerint, ahol az adagolandó készítményben levő interferon-alfa-2b-nek és tmietioninnak legalább 30°'k-a a bazárt olaj-a-vízben emulzióban van jelen
- 11, A készítmény alkalmazásra a 8. igénypont szerint, éhé! az adagolás legalább: hetente 3 napon végzendő, legalább 6 heten át, ff, ifárás meltlliméiirls:: tpivézlkelymet «áimázl: kéÉMM vezlkdldm készitminy éiSállltásira, amelynek: során (a) biztosítunk egy vizes emulzuátázlst, amely tartalmaz vizet és felületaktív anyagot, valamint az emulzióba Inkorgerltf /Ébfláhr^ lnterferdb-éftéw3b-t él 0,01 - 0.5 tdmeg% t-meiionint. a vizes fázis továbbá tartalmaz további átilWiiéb keláfképzö-szert ésivagy proteínstabilizilorf; és (b) a vizes ernulzkífázist keverjük olajat és konzlsztenciaerősito anyagét fiiilriilé: llszpergáít fázissal oly módon, hogy a diszpergáii fázist iiszpergilfyk a vizes emulzléfázlsban:; ahol; a kiszffmfny humán interféranva!fa-2bmktiy|aáa a készítmény 1 grammjára vonatkoztatva kOröibélÖff ~ 10 WIO< i|: & 12. igénypont szenntl eliris, ebei a dlszpemál fizls 1 ptTt-nél ktseob mérete oiajcseppekei tarfálmaz, 14, A 12. vagy 13, igénypont szerinti eljárás, ahol a multkamelíáns vezikulum
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90932407P | 2007-03-30 | 2007-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE033256T2 true HUE033256T2 (hu) | 2017-11-28 |
Family
ID=39807744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE08733666A HUE033256T2 (hu) | 2007-03-30 | 2008-03-27 | Kétfázisú lipidvezikulum készítmény és eljárás cervikális diszplázia kezelésére intravaginális adagolással |
Country Status (18)
Country | Link |
---|---|
US (3) | US8945529B2 (hu) |
EP (1) | EP2134353B1 (hu) |
JP (1) | JP5587762B2 (hu) |
KR (1) | KR20090130081A (hu) |
AU (1) | AU2008234364B2 (hu) |
CA (1) | CA2681565C (hu) |
CY (1) | CY1118794T1 (hu) |
DK (1) | DK2134353T3 (hu) |
ES (1) | ES2617063T3 (hu) |
HR (1) | HRP20170250T1 (hu) |
HU (1) | HUE033256T2 (hu) |
LT (1) | LT2134353T (hu) |
MX (1) | MX2009010405A (hu) |
PL (1) | PL2134353T3 (hu) |
PT (1) | PT2134353T (hu) |
SI (1) | SI2134353T1 (hu) |
TW (1) | TWI440477B (hu) |
WO (1) | WO2008119160A1 (hu) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3008900B1 (fr) * | 2013-07-25 | 2018-03-30 | Centre Nat Rech Scient | Nanoparticules lipidiques multicompartimentees |
US10159646B2 (en) * | 2013-08-12 | 2018-12-25 | Altum-Avro Pharma Partnership | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
US8986732B2 (en) * | 2013-08-12 | 2015-03-24 | Helix Biopharma Corporation | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US20150147382A1 (en) * | 2013-09-23 | 2015-05-28 | Exir Nano Sina Company | Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same |
WO2018213789A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Modified messenger rna comprising functional rna elements |
WO2018213932A1 (en) * | 2017-05-26 | 2018-11-29 | Altum Pharmaceuticals Inc. | Biphasix cannabinoid delivery |
EP3714048A1 (en) | 2017-11-22 | 2020-09-30 | Modernatx, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
WO2019104160A2 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
US20230009009A1 (en) | 2018-09-13 | 2023-01-12 | Modernatx, Inc. | Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease |
MA53615A (fr) | 2018-09-14 | 2021-07-21 | Modernatx Inc | Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar |
JP2022549216A (ja) * | 2019-09-23 | 2022-11-24 | ディーディーエス リサーチ インク. | 浸透促進剤を含有する脂質ベシクル組成物 |
WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
WO2022204380A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
US20240207374A1 (en) | 2021-03-24 | 2024-06-27 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
WO2022271776A1 (en) | 2021-06-22 | 2022-12-29 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
TW202412818A (zh) | 2022-07-26 | 2024-04-01 | 美商現代公司 | 用於暫時控制表現之經工程化多核苷酸 |
WO2024130158A1 (en) | 2022-12-16 | 2024-06-20 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
WO1995003787A1 (en) * | 1993-07-28 | 1995-02-09 | University Of Saskatchewan | Biphasic multilamellar lipid vesicles |
IN184589B (hu) * | 1996-10-16 | 2000-09-09 | Alza Corp | |
US5993852A (en) * | 1997-08-29 | 1999-11-30 | Pharmaderm Laboratories Ltd. | Biphasic lipid vesicle composition for transdermal administration of an immunogen |
US6656499B1 (en) * | 1999-11-12 | 2003-12-02 | Pharmaderm Laboratories, Ltd. | Composition for transdermal and dermal administration of interferon-α |
TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
EP1576952A1 (en) * | 2004-03-18 | 2005-09-21 | OctoPlus Technologies B.V. | Hydrogel microspheres with improved release profile |
-
2008
- 2008-03-27 WO PCT/CA2008/000563 patent/WO2008119160A1/en active Application Filing
- 2008-03-27 AU AU2008234364A patent/AU2008234364B2/en active Active
- 2008-03-27 DK DK08733666.5T patent/DK2134353T3/en active
- 2008-03-27 MX MX2009010405A patent/MX2009010405A/es active IP Right Grant
- 2008-03-27 PL PL08733666T patent/PL2134353T3/pl unknown
- 2008-03-27 HU HUE08733666A patent/HUE033256T2/hu unknown
- 2008-03-27 KR KR1020097022186A patent/KR20090130081A/ko not_active Application Discontinuation
- 2008-03-27 PT PT87336665T patent/PT2134353T/pt unknown
- 2008-03-27 SI SI200831765A patent/SI2134353T1/sl unknown
- 2008-03-27 US US12/532,752 patent/US8945529B2/en active Active
- 2008-03-27 ES ES08733666.5T patent/ES2617063T3/es active Active
- 2008-03-27 LT LTEP08733666.5T patent/LT2134353T/lt unknown
- 2008-03-27 JP JP2010500036A patent/JP5587762B2/ja active Active
- 2008-03-27 CA CA2681565A patent/CA2681565C/en active Active
- 2008-03-27 EP EP08733666.5A patent/EP2134353B1/en active Active
- 2008-03-28 TW TW097111592A patent/TWI440477B/zh active
-
2013
- 2013-03-22 US US13/849,451 patent/US20130216610A1/en not_active Abandoned
- 2013-03-22 US US13/849,455 patent/US20130224283A1/en not_active Abandoned
-
2017
- 2017-02-14 CY CY20171100200T patent/CY1118794T1/el unknown
- 2017-02-16 HR HRP20170250TT patent/HRP20170250T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CA2681565C (en) | 2016-10-25 |
HRP20170250T1 (hr) | 2017-04-07 |
US8945529B2 (en) | 2015-02-03 |
TWI440477B (zh) | 2014-06-11 |
AU2008234364A1 (en) | 2008-10-09 |
JP5587762B2 (ja) | 2014-09-10 |
ES2617063T3 (es) | 2017-06-15 |
WO2008119160A1 (en) | 2008-10-09 |
TW200846030A (en) | 2008-12-01 |
EP2134353A1 (en) | 2009-12-23 |
LT2134353T (lt) | 2017-03-27 |
US20130224283A1 (en) | 2013-08-29 |
PT2134353T (pt) | 2017-02-15 |
JP2010522698A (ja) | 2010-07-08 |
KR20090130081A (ko) | 2009-12-17 |
PL2134353T3 (pl) | 2017-06-30 |
CY1118794T1 (el) | 2017-07-12 |
EP2134353A4 (en) | 2013-08-07 |
AU2008234364B2 (en) | 2013-10-17 |
US20130216610A1 (en) | 2013-08-22 |
SI2134353T1 (sl) | 2017-03-31 |
CA2681565A1 (en) | 2008-10-09 |
MX2009010405A (es) | 2010-02-03 |
DK2134353T3 (en) | 2017-02-20 |
EP2134353B1 (en) | 2016-11-16 |
US20100196453A1 (en) | 2010-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008234364B2 (en) | Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery | |
US5853755A (en) | Biphasic multilamellar lipid vesicles | |
KR0157428B1 (ko) | 비 전달용 지질부형제와 그 사용법 | |
DE69937546T2 (de) | Mischmizell-arzneistoffverabreichungssystem und verfahren zu dessen herstellung | |
Naguib et al. | Optimizing novel penetration enhancing hybridized vesicles for augmenting the in-vivo effect of an anti-glaucoma drug | |
Jain et al. | Proultraflexible lipid vesicles for effective transdermal delivery of levonorgestrel: development, characterization, and performance evaluation | |
JP4755742B2 (ja) | 医薬最終処方物におけるナノディスパージョンの使用 | |
JP2001524958A (ja) | 新規な液晶をベースとする生物接着性薬剤送出系 | |
CA2172110A1 (en) | Pharmaceutical carriers for nanosuspensions | |
EP0711148B1 (en) | Biphasic multilamellar lipid vesicles | |
US6656499B1 (en) | Composition for transdermal and dermal administration of interferon-α | |
Gupta et al. | Ethosomes as elastic vesicles in transdermal drug delivery: An overview | |
Foldvari et al. | Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery | |
US20130085146A1 (en) | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues | |
Gadekar | Formulation and evaluation of naproxen proniosomal gel for the treatment of inflammatory and degenerative disorders of the musculoskeletal system | |
CA2957641A1 (en) | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intra vaginal delivery | |
CA2957645C (en) | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intra vaginal delivery | |
JPH10316555A (ja) | 高分子化合物を含有するリポソーム外用剤 | |
KR20080086736A (ko) | 이트라코나졸을 함유한 마이크로이멀젼계 하이드로겔 및이의 제조방법 | |
US20230093908A1 (en) | In-situ Gel Containing Cyclosporine Micelles as Sustained Ophthalmic Drug Delivery System | |
JP2023544728A (ja) | 扁平苔癬の治療のための局所ルキソリチニブ | |
KR20140046499A (ko) | 무복계면 암포테리신 및 그 제조방법 |